Clinical neuropharmacology
-
Clin Neuropharmacol · Sep 2009
Randomized Controlled Trial Comparative StudyEfficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.
To assess the impact of the new botulinum neurotoxin type A preparation NT 201 (Xeomin; Merz Pharmaceuticals GmbH, Frankfurt, Germany) on muscle tone, functional disability, and caregiver burden in patients with poststroke upper limb spasticity in a randomized, placebo-controlled, double-blind study. ⋯ NT 201 led to statistically significant improvements in muscle tone and disability and was well tolerated in patients with poststroke upper limb spasticity.